Development of new anticoagulants: present and future.

  • Job Harenberg
  • Published 2008 in Seminars in thrombosis and hemostasis

Abstract

Anticoagulant drugs are the most frequently hospital-prescribed compounds in many countries and are used with the intention to prevent and treat venous and arterial thromboembolism. Because of side effects and the necessity of dose adjustment of unfractionated heparins and coumarins, low-molecular-weight heparins, heparinoids, and direct systemically applied thrombin inhibitors were developed. Because of limitations of these anticoagulants, synthetic indirect and direct factor Xa inhibitors and direct thrombin inhibitors were further developed with the aim to improve the benefit/risk ratio for anticoagulant therapy of patients using a simplified mode of action. This overview describes the results of some recent studies of these inhibitors of blood coagulation.

DOI: 10.1055/s-0029-1145260

9 Figures and Tables

Statistics

050100200920102011201220132014201520162017
Citations per Year

102 Citations

Semantic Scholar estimates that this publication has 102 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Harenberg2008DevelopmentON, title={Development of new anticoagulants: present and future.}, author={Job Harenberg}, journal={Seminars in thrombosis and hemostasis}, year={2008}, volume={34 8}, pages={779-93} }